Garami, Z., Hascsi, Z., Varga, J., Dinya, T., Tanyi, M., Garai, I., Damjanovich, L. and Galuska, L. (2012) The Value of FDG-PET in Early Stage Breast Cancer Compared to Traditional Diagnosis Modalities with an Emphasis on Changes in Disease Stage Designation and Treatment Plan. The Journal of Cancer Surgery. EJSO, 38, 31-37.
https://doi.org/10.1016/j.ejso.2011.09.002

has been cited by the following article:

• TITLE: The Role of 18F-FDG PET/CT in Staging Breast Carcinoma in Hanoi Oncology Hospital, Vietnam

  AUTHORS: Cuong Duy Dang, Thang Van Nguyen, Tuynh Van Chu, Huy Quang Pham

  KEYWORDS: 18F-FDG PET/CT (Positron Emission Tomography with 2-Deoxy-2-[Fluorine-18]Fluoro-D-Glucose Integrated with Computed Tomography), Breast Carcinoma, Staging, SUV (Standardized Uptake Value)

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.10 No.1, January 27, 2022

  ABSTRACT: Purpose: This study aimed to evaluate the role of 18F-FDG PET/CT scans in staging breast carcinoma. Materials and Methods: A descriptive study on 46 patients who were diagnosed with breast carcinoma in Hanoi Oncology Hospital, Vietnam from June 2019 to June 2021. Those patients underwent 18F-FDG PET/CT scans for pre-treatment staging. Results: There was a positive correlation between the size of primary tumors and their SUV (p 18F-FDG PET/CT were 75% and 100%, respectively. The rate of distant metastasis detection was 15.2% (7/46 patients). Metastatic lesions were found in bone, lungs, liver, and lymph nodes. There was a significant difference in SUV among organs (p 18F-FDG PET/CT. After PET/CT, 17.4% patients (8/46) had their treatment plan changed. Conclusions: 18F-FDG PET/CT plays an important role in staging breast carcinoma. Determining accurately the breast carcinoma stage by 18F-FDG PET/CT could help alter treatment strategy to best suit with patients, and avoid unnecessary surgery.